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Breast cancer rates and median age of onset differ between Western Europe and North Africa. In Western 
populations, 5 to 10 % of breast cancer cases can be attributed to major genetic factors such as BRCA1 and 
BRCA2, while this attribution is not yet well defined among Africans. To help determine the contribution of 
BRCA1 mutations to breast cancer in a North African population, we analysed genomic DNA from breast cancer 
cases ascertained in Algiers.  
Both familial cases (at least three breast cancers in the same familial branch, or two with one bilateral or 
diagnosed before age 40) and sporadic cases less than 38 years of age were studied. Complete sequencing plus 
quantitative analysis of the BRCA1 gene was performed. 9.8 % (5/51) of early-onset sporadic and 36.4 % (4/11) of 
familial cases were found to be associated with BRCA1 mutations. This is in contrast 10.3 % of French HBOC 
families exhibiting a BRCA1 mutation. One mutation, c.798_799delTT, was observed in two Algerian families and 
in two families from Tunisia, suggesting a North African founder allele. Algerian non-BRCA1 tumors were of 
significantly higher grade than French non-BRCA tumors, and the age at diagnosis for Algerian familial cases was 
much younger than that for French non-BRCA familial cases. In conclusion, we observed a much higher 
frequency of BRCA1 mutations among young breast cancer patients than observed in Europe, suggesting 
biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the 
Northern African population. 
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Introduction 
BRCA1 mutations are responsible for a significant 
proportion of hereditary breast and ovarian cancer 
(HBOC) families. BRCA1 is responsible for more than 
50 % of HBOC families with at least four cancer cases 
[1], and of ~15 % of families overall. In Western 
populations, an inherited mutation of this gene confers 
a lifetime risk of breast cancer of up to 80 %, with up to 
40 % of carriers developing breast cancer by the age of 
50 [2]. Penetrance may be modified by other risk or 
protective genes or environmental factors, most 
notably reproductive history and diet. The effect of 
lifestyle on penetrance of BRCA mutations is 
significant, as studies of western populations show 
that carriers born after 1940 have much higher breast 
cancer incidence and earlier onset than carriers born 
before 1940 [3]. 
Studies of breast cancer in the Maghreb 
(including Morocco, Algeria, Tunisia, Lybia and 
Mauritania) have shown striking differences in breast 
cancer patterns. Age-standardized incidence per 
100,000 for breast cancer in 2002 was 23.5 in Algeria 
versus 91.9 in France [4]. The size and grade of breast 
tumors in the Maghreb are increased, while the 
median age of onset (48) is more than ten years 
younger than the European/North American median 
of 61 [5]. About 11 % of breast cancer cases in Algeria 
occur in women < 35 years old, and 55 % of cases at < 
50 years. These differences may be due to differences 
in exposure to female hormones, diet, physical activity, 
or other factors. Int. J. Med. Sci. 2008, 5 
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The combination of lower incidence and lower 
age of onset of breast cancer in the Maghreb suggests 
that the contribution of genetic factors such as 
mutation of BRCA1 m a y  c o n t r i b u t e  t o  a  l a r g e r  
proportion of breast cancer overall. We therefore set 
out to determine the contribution of mutations in the 
BRCA1 gene to breast c ancer in Algeria. This was a 
pilot study to determine inclusion criterea for more 
widespread molecular diagnostic analysis of at-risk 
women in the Maghreb. We used the same criterea to 
define ‘familial’ cases that we use in our molecular 
diagnostic laboratory in France, and then added 
early-onset sporadic cases. All exons and 
splice-junctions of BRCA1 were amplified and 
sequenced. The MLPA method was used to detect 
larger deletions and duplications of the gene. 
Methods 
Breast cancer cases were identified at the Pierre 
and Marie Curie Hospital in Algiers and chosen 
according to the following criterea: age at diagnosis < 
38 years for sporadic cases; two or more first degree 
relatives with breast or ovarian cancer for familial 
cases. No families with ovarian cancer were 
ascertained. Approval was obtained from local 
institutional review boards, and each patient gave 
written informed consent. Peripheral blood was drawn 
from 51 early onset sporadic cases (average age at 
diagnosis 31.5 + 4.5, range 15 to 38) and 13 cases from 
11 breast cancer families (average age at diagnosis 37.2 
+ 6.8, range 28 to 52). 
DNA was extracted from 0.2 ml of peripheral 
blood using the QIAamp DNA Blood Mini kit (Qiagen, 
Courtaboeuf, France). All exons and > 50 bp of each 
flanking intron were amplified in 15 μl with 50ng 
DNA, 1x reaction buffer, 0.3 mM dNTPs, 1 nM 
primers, and 0.5 units Taq polymerase (primers from 
MWG Biotech, Ebersberg, Germany; all other reagents 
from Applied Biosystems, Courtaboeuf, France). 
Sequences available on request. PCR was performed in 
an MWG Bioblock thermocycler with initial 
denaturation at 94°C for 2min, followed by 30 to 35 
cycles of (94°C 20s, 54°C 20s, 72°C 20s), except for 
exons 7 (15 cycles of 94°C 20s, 60°C 10s, 72°C 20s then 
25 cycles of 94°C 20s, 56°C 15s, 72°C 20s) and 23 (5 
cycles of 94°C 20s, 57°C 20s, 72°C 20s then 30 cycles of 
94°C 20s, 53°C 20s, 72°C 20s). Exon 11 was analysed in 
nine overlapping PCR fragments. PCR products were 
purified by membrane retention (Multiscreen PCR, 
Millipore, Molsheim, France) and resuspended in 25 μl 
of water; 3 μl was then sequenced in a total of 8 μl 
using 1 nM primer and 3 μl of Big Dye v3 reagents 
(Applied Biosystems, Courtaboeuf, France), purified 
over sephadex (Amersham Biosciences, Orsay, 
France), 10 μl of deionized formamide (Applied 
Biosystems, Courtaboeuf, France) added, and then 
resolved on a 3100 sequencer (Applied Biosystems, 
Courtaboeuf, France).   
Sequences were compared to the BRCA1 genomic 
and cDNA reference sequences (Accession N°s 
L78833.1 and U14680 respectively) using Seqman 
software (Lasergene, Madison WI, USA). All 
mutations were confirmed on an independent second 
amplification and a second DNA sample where 
possible. Nucleotide numbering of all mutations and 
polymorphisms is in reference to the coding sequence, 
with the A of the initiating ATG = 1. 
Samples for which no point mutation was found 
were analysed by MLPA for large deletions or 
duplications according to the manufacturer’s protocol 
(MRC Holland) (protocol available on request). 
Haplotypes were determined at the following 
loci: D17S1321, D17S855, D17S1322, D17S1323, and 
D17S1327 (references and primer sequences NCBI) 
using PCR with fluorescent forward primers and 
analysis with Genescan software (Applied Biosystems, 
Courtaboeuf, France) as well as at biallelic 
polymorphisms in the coding sequence. 
Statistical analysis used the chi-squared test, with 
p < 0.05 taken as the threshold for significant 
difference. 
Results 
Five deleterious mutations among the 51 
early-onset sporadic cases were observed, and four 
mutations among the 11 families (Table 1). Two 
non-conservative missense variants, c.425C>A 
(p.Pro142His) and c.4072G>A (p.Gly1358Lys), and an 
intronic transversion with weak potential to affect 
splicing of exon 24, c.5467-10C>A (IVS23-10C>A), 
were observed in three sporadic cases: it is not 
currently known if these are deleterious mutations or 
rare polymorphisms. Other rare polymorphisms or 
conservative missense variants of unknown effect 
were also observed in some sporadic cases; none were 
predicted to affect splicing. 
The c.798_799delTT mutation observed in 
families 1351 and 1612 was also observed in two 
families from Tunisia (data not shown). Microsatellite 
markers in and flanking the BRCA1 locus showed a 
common haplotype in all c.798_799delTT carriers. 
Complete sequencing also provided data on snps 
in the coding sequence, allowing the construction of 
haplotypes. For a core of nine snps, 18 different 
haplotypes were observed for the 128 chromosomes 
studied (Table 2). The most common, observed 74 
times, corresponded to the major canonical haplotype, 
H1, found by Judkins et al [6]. Additional snps Int. J. Med. Sci. 2008, 5 
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dividing this canonical haplotype into three others 
were not informative in our study. Two other 
haplotypes described in that study of a North 
American / European population were also observed, 
H7 and H10, as well as a total of four copies of three 
haplotypes described in the Tunisian population [7]. 
The remaining 46 Algerian chromosomes carried 12 
different haplotypes not described in either previous 
study; one of these was the second most frequent 
haplotype observed, at 18 copies. Six haplotypes were 
limited to single homozygous individuals. 
Quantitative analysis of BRCA1 exons did not suggest 
any large deletions that could confound homozygosity 
with hemizygosity.  
There was no significant difference in the average 
age of mutated sporadic cases (32.8 + 5.0 years) versus 
non-mutated sporadic cases (31.3 + 4.4 years), nor 
between familial mutated vs non-mutated cases (38.4 + 
4.8 vs 35.7 + 8.9 years, respectively). Algerian familial 
cases, regardless of BRCA status, were similar to 
French BRCA1 cases (37.2 + 6.3 vs 41.2 + 10.4; p = 0.19), 
younger than French BRCA2 cases (47.5 + 14.5; p = 
0.015) and much younger than French non-BRCA 
familial cases (50.7 + 12, p = 0.00017). 
Tumor characteristics were compared between 
BRCA1 heterozygotes and non-heterozygotes in the 
two populations (Table 3). All tumors of medullary 
histology were observed in BRCA1 heterozygotes. 
BRCA1 tumors tended to be of higher grade in both 
populations, as expected; however, Algerian 
non-BRCA1 cases included a significant excess of high 
grade tumors (p < 0.001). Significantly more Algerian 
non-BRCA1 tumors were ER-negative and 
node-positive, compared to French non-BRCA1 tumors 
(p < 0.001 and p < 0.002, respectively), consistent with 
their higher grade tumors. 
Table 1. Characteristics of patients with BRCA1 mutations or unclassified variants.  
Case mutation  effect    Sporadic 
or fa-
milial 
Age at 
diagnosis
histology size grade ER PR nodes  Age  at 
menarche 
parity nursing BMI
1357-01 c.46_74del29  p.Asn16fs  Sporadic 29  Papillary  4 cm III  - - n.i 14  0  0  21.3
1490-01 c.46_74del29  p.Asn16fs  Familial  37 + 44  atypical medullar, 
atypical ductal 
3 cm --  n.i. n.i 0/1  n.i  n.i  n.i  34.2
1358-01 c.83_84delTG  p.Arg28fs  Sporadic 26  Poorly differentiated 
ductal  
1 cm II  - - 0/11 12  0  0  20.3
1497-01 c.202+1G>A  Splice do-
nor 
Familial 38  Atypical  infiltrating 
ductal 
9 cm III  + + 1/14 n.i  n.i  n.i  n.i 
1497-02    exon 5    42  polymorphic infiltrating 
ductal 
3.5 
cm 
III  - - 3/10 15  6  54  m  22.7
1612-01 c.798_799delTT p.Val266fs  Familial  43  polymorphic infiltrating 
ductal 
0.7 
cm 
II n.i. n.i 0/12  15  3  72  m  21.8
1351-01 c.798_799delTT p.Val266fs  Familial  32  infiltrating ductal  6 cm II  n.i. n.i 11/20 12  0  0  21.6
1351-02       33  n.i.                   
1370-01 c.1817delC  p.Pro606fs  Sporadic 37  atypical infiltrating duc-
tal 
4 cm III  n.i. -  4/11 12  0  0  26.0
1614-01 c.2745dupT  p.Ser915fs Sporadic  36  Sarcomatoid  carcinoma 5  cm III  n.i. -  1/10 12  6  36  m   
1470-01 c.3715delT  p.Ser1239fs Sporadic 36  Infiltrating  3.5 
cm 
II n.i. n.i 0/18  12  3  72  m  22.6
Samples with unclassified variants that may be involved in breast cancer 
1620-01 c.425C>A  Pro142His  Sporadic 26  infiltrating ductal  1.5 
cm 
III n.i. +  14/18  14  0  0  23.9
1355-01 c.4072G>A  Glu1358Lys  Sporadic 35  infiltrating ductal + in 
situ 
n.i. n.i.  n.i. n.i. n.i.  n.i.  n.i.  n.i.  n.i. 
1468-01 Ivs23-10C>A  **  Sporadic 28  Atypical ductal  3 cm III  n.i. n.i. 1/1  12  0  0  20.9
Samples with unclassified variants that are not likely to be involved in breast cancer 
c.981A>G Thr327Thr  Sporadic  34  Polymorphic  ductal 0.3  II  n.i. +  1/21  12  0  0  28.6
c.2733G>A Gly911Gly                        
1476-01 
c.3024G>A Met1008Ile                        
c.981A>G Thr327Thr  Sporadic  37  infiltrating  galactophoric 7  cm II  n.i. n.i. 0/1  13  2  0  21.0
c.2733A>G Gly911Gly                        
1494-01 
c.3024G>A Met1008Ile                        
1493-01 c.4883T>C  Met1628Thr Sporadic 38 (?)  n.i.  n.i.  n.i  n.i. n.i. n.i  n.i.  n.i.  n.i  n.i 
1488-01 c.4956G>A  Met1652Ile  Sporadic 26  infiltrating ductal  2.5 
cm 
II +  -  pos  n.i.  n.i.  n.i.  n.i. 
1480-01 c.5117G>C  Gly1706Ala  Sporadic 36  infiltrating ductal + in 
situ 
2 cm n.i.  n.i. n.i 1/10  n.i.  n.i.  n.i.  n.i. 
1610-01 c.5117G>C  Gly1706Ala Familial  29  infiltrating ductal  5 cm III  - +  3/26 13  2  6  m  27.3
1362-01 c.5175A>G  Glu1725Glu Sporadic 32  Micro-infiltrating ductal 5.5 
cm 
II n.i. n.i. 0/13  12  3  16  m  22.8
n.i. no information, ** slight potential to splice exon 24 eight nucleotides early (listed as an unclassified variant in the BIC by Myriad). Int. J. Med. Sci. 2008, 5 
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Table 2. BRCA1 Haplotypes among Algerian breast cancer patients 
Snp\Haplotype   H1   H7   H10   T2   T4   T17   A1   A2   A3   A4   A5   A6   A7   A8   A9   A10   A11   A12 
c.2077A  0 0 0  0 0 0  0 0 0 0 0 0 1 1 1 0  0  0 
c.2082T  0 0 0  0 0 0  0 0 0 1 1 1 1 1 1 1  1  1 
c.2311C  0 0 0  0 0 0  0 1 1 1 1 1 0 1 1 1  0  1 
c.2521C  0 0 1  1 0 0  0 0 0 0 0 0 0 0 0 0  0  0 
c.3113G  0 0 0  0 0 0  0 1 1 1 1 1 1 1 1 1  0  1 
c.3119G  0 1 0  0 0 0  0 0 0 0 0 0 0 0 0 0  1  0 
c.3548G  0 0 0  0 1 0  1 1 1 0 1 1 1 1 1 1  0  1 
c.4308C  0 0 0  0 0 0  1 1 1 1 1 1 1 1 1 1  1  0 
c.4837G  0 0 0  1 0 1  0 0 1 0 0 1 0 1 0 0  1  0 
Times  appearing  74  4 2  1 2 1  2 2 2 2 5 18  2 7 1 1  1  1 
% of 128 alleles  57.8  3.1  1.5  0.8 1.5 0.8  1.5 1.5  1.5 1.5 3.9 14  1.5 5.5  0.8  0.8 0.8 0.8 
         *   * * * *     *          
H1, H7 and H10 are described by Judkins et al [6]; T2, T4 and T17 correspond to haplotypes described by Troudi et al [7] ; A1 through A12 
were unique to the Algerian population. 0 indicates the nucleotide corresponding to the reference sequence ; 1 to the variant nucleotide. 
Asterisk indicates a haplotype unique to a homozygous individual. 
Table 3. Comparison of tumor characteristics from mutated and non-mutated cases, from Algeria and France. 
  BRCA1, Algiers  Non-BRCA1, Algiers  BRCA1, France  Non-BRCA, France* 
Age at diagnosis  36.1 + 5.5**  31.7 + 5.4***  41.2 + 10.4  50.7 + 12.2 
Grade 1  1 of 10 (10 %)  1 of 43 (2 %)  2 of 39 (5 %)  32 of 115 (28 %) 
Grade 2  3 of 10 (30 %)  25 of 43 (58 %)  10 of 39 (26 %)  67 of 115 (58 %) 
Grade 3  6 of 10 (60 %)  17 of 43 (40 %)  27 of 39 (69 %)  16 of 115 (14 %) 
Size  3.8 cm  3.4 cm  2.0 cm  2.2 cm 
Medullary histology  1 of 12  0 of 48  6 of 49  0 of 139 
ER, pos/tested  1/5 (20 %)  3/15 (20 %)  5/14 (36 %)  45/63 (71 %) 
PR, pos/tested  2/6 (33 %)  18/32 (56 %)  4/14 (29 %)  35/64 (55 %) 
Node positive  6 of 10 (60 %)  29 of 42 (69 %)  13 of 31 (42 %)  41 of 102 (40 %) 
* non-BRCA cases were found to be negative for mutations in both BRCA1 and BRCA2; ** includes 5 cases selected for age < 38 years; *** 
includes 46/52 cases selected for age < 38 years. 
Discussion  
The types of BRCA1 mutations in this sample of 
the Algerian population were typical of those observed 
elsewhere, with six different deletions or duplications 
involving one to 29 nucleotides, and a novel change in 
the donor splice site of exon 5. Two nonconservative 
substitutions of amino acids were observed, as well as 
an intronic transversion with some potential to affect 
splicing of exon 24, possibly representing novel 
mutations in this population. Several uncommon silent 
or conservative sequence variants were also observed.  
We observed one deleterious mutation, 
c.798_799delTT, in two Algerian families and also in 
two Tunisian breast cancer families (data not shown), 
suggesting the first non-Jewish founder mutation to be 
described in Northern Africa. This mutation is cited 
twice in the BIC database, without any ethnic origin 
indicated. Analysis of five microsatellite markers 
showed a common haplotype associated with this 
mutation in all our known carriers. None of the 
founder mutations previously observed among middle 
eastern (Iranian) or Jewish populations were found.  
Haplotype analysis revealed the genetic diversity 
of the Algerian population. A large study of North 
Americans and European revealed 10 canonical 
haplotypes clustered around two major haplotypes 
both diverged from a common ancestor [6]. Analysis of 
the Tunisian population revealed several new 
haplotypes, in concordance with the great age of this 
population [7]. In keeping with this, the Algerian 
population also exhibited several unique haplotypes as 
well as three in common with the Tunisian population. 
Three haplotypes could be considered ‘common’, 
accounting for 58, 14 and 5.5 % of observed 
chromosomes. All the Algerian haplotypes appeared 
to be derived from the major H1 chromosome 
described by both Judkins and Troudi; none appeared 
related to the other major haplotype, H2. Interestingly, 
several rare haplotypes occurred as homozygotes. 
Although we have no information on the precise 
geographic or tribal origin of the families, we speculate 
that this may reflect the insular nature of rural Algeria, 
where the coefficient of inbreeding is relatively high 
and genetic drift may establish unique regional 
haplotypes. No homozygosity for unclassified variants 
was observed. 
The age at which familial Algerian cases, 
regardless of BRCA1 status, developed breast cancer 
was similar to our BRCA1-positive French families, but 
significantly younger than French familial non-BRCA 
or  BRCA2 cases. Young age at diagnosis is an 
indication for referral for BRCA testing, and the older 
age at cancer in BRCA-negative families is common. Int. J. Med. Sci. 2008, 5 
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That familial cases from the Maghreb without BRCA1 
mutation resemble BRCA1 families may be related to 
the lower age of onset and higher frequency of high 
grade tumors overall for breast cancer in this 
population. 
The characteristics of BRCA1-related tumors were 
similar between Algerian and French patients, 
allowing for larger tumor size probably associated 
with later diagnosis of Algerian cases. In contrast, the 
non-BRCA1 tumors from Algeria were also of 
significantly higher grade, presented more positive 
nodes and were less frequently ER-positive than 
French non-BRCA tumors. This excess of high-grade 
tumors in African populations has been described 
before, with 65 to 86 % of tumors being grade II or III 
[8-10]. Frequently positive nodes and negative 
hormone receptor status are both consistent with 
high-grade tumors. Low- and high-grade breast 
cancers may represent separate pathways of 
oncogenesis [11], thus the absence of low grade tumors 
is not explained by delay in diagnosis allowing 
‘progression’ to a higher grade. The marked difference 
in distribution of breast tumor grades between 
Western and Middle-Eastern/African societies merits 
further study. One possibility is that low-grade tumors 
either arise infrequently or do arise but don’t develop 
into palpable tumors initiating medical care. This 
relative absence of low-grade tumors may contribute 
to the lower incidence of breast cancer overall in 
African countries. It may also reflect an ascertainment 
bias: Western societies have instituted widespread 
screening programs detecting small low-grade tumors 
that may go undeclared in developing societies. Two 
arguments for the biological basis of this difference 
have been proposed. First, migrants from 
low-incidence countries gradually take on some of the 
risk of breast cancer of their host countries, and their 
descendants have a risk of breast cancer corresponding 
to the host country [12, 13], arguing for environmental 
and lifestyle factors in the difference in incidence. On 
the other hand, studies in the United States have 
shown that breast cancer in African-American women 
is associated with higher grade and poorer prognosis, 
arguing a biological difference even after 
socio-economic differences are controlled, and 
reflecting breast cancer statistics for sub-Saharan 
Africa [14]. 
Environmental and lifestyle factors may be 
largely responsible for the low incidence of breast 
cancer in the Maghreb. These factors are difficult to 
identify precisely, but their combined effect has 
serious consequences, as the clear increase in breast 
cancer incidence in American Ashkenazi BRCA 
carriers born after vs before 1940 shows [3].  
 Protective reproductive factors tend to diminish 
as societies become “westernized” and women delay 
and limit their families. The protective effect of 
pregnancy is associated with younger age at first 
pregnancy as well as with increasing parity, while 
longer breastfeeding has an independent protective 
effect [15, 16]. Parity levels are converging for Europe 
and the Maghreb, with 6.49 children per woman in 
Algeria and 1.87 in France in 1980-1985, but 2.53 in 
Algeria and 1.87 in France in 2000-2005 
(http://www.un.org/esa/population/ordering.htm). 
In the present study, parity was lower among women 
from Algeria (1.84 + 2.04) than from France (2.18 + 
1.52), probably because many of the women in our 
study were of childbearing age and had not completed 
their families (whereas there are many more older 
carriers in our french families).  
It thus seems that a major protective factor in the 
Algerian population is rapidly disappearing; the 
reduction in parity is likely accompanied by increased 
age at first pregnancy and reduced duration of 
breastfeeding. This change in lifestyle may soon be 
reflected in increased breast cancer incidence as this 
cohort of women reaches the age at which breast 
cancer is most prevalent. Other lifestyle factors that 
may have contributed to breast cancer risk in western 
populations for multiple generations now but which 
have only more recently begun to affect the Magrheb 
include the use of oral contraceptives, less physical 
activity, increased use of refined foods and chemical 
food additives, and decreased intake of fresh fruits and 
vegetables. 
Single cases are not generally accepted for genetic 
testing for hereditary breast cancer genes without a 
strong implication of hereditary factors, such as young 
age at diagnosis (< 35 years), multifocal or bilateral 
tumors, and/or medullar histology. In most western 
populations such testing is not cost-effective, with only 
2.6 % of 2-case families in Finland being positive for a 
BRCA mutation [17], and very few sporadic cases 
being positive in the US. Other studies, however, 
suggest that testing of 2-case families or single cases 
before age 36 can be efficient in certain populations [18, 
19]. The 9.8 % BRCA1 mutation frequency we observed 
in young sporadic cases in Algeria is remarkable in 
comparison to these other populations. At least two 
explanations may contribute to this observation: the 
misclassification of familial cases, and a different 
population structure in Algeria, with a relatively low 
incidence of breast cancer revealing the greater 
contribution of genetic factors. 
Although our sporadic cases did not signal any 
family history of breast or ovarian cancer, the stigma 
attached to cancer in this society makes it is possible Int. J. Med. Sci. 2008, 5 
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that they were not aware of a positive history. Our 
discussions with familial cases showed that women 
with breast cancer often hid this diagnosis from their 
close relatives. At this time, the medical structures in 
place, such as cancer registries, are not sufficient to 
ascertain family history other than by asking the index 
case. 
The second hypothesis, that of the relatively 
greater contribution of genetic factors in a population 
where the overall incidence of breast cancer is low, 
would suggest a greater proportion of familial vs 
sporadic cases. Although we have not yet performed a 
population-based study to determine this ratio, the 
high frequency of BRCA1 mutation in isolated cases 
may indicate that this is the case, especially if the 
penetrance of BRCA1 mutations is lower in this 
population. The protective lifestyle factors discussed 
above may have spared the relatives of our young 
isolated carriers from breast cancer in spite of their 
carrier status. Thus the western BRCA1 model where 
most mutations manifest in familial aggregations of 
breast and/or ovarian cancer with penetrance for 
breast cancer of 50 % by age 50, may be expressed 
differently in the Maghreb, where mutations are found 
in familial cancer but also in a significant proportion of 
isolated cases, penetrance is reduced. It remains to be 
seen whether recent changes in lifestyle will increase 
the incidence of breast cancer in carrier families. 
In conclusion, our findings suggest that the 
norms of accepting breast cancer cases for BRCA 
analysis must be adapted to the population. We are 
extending our study to additional cases and families 
f r o m  A l g e r i a ,  a n d  h o p e  t o  s o o n  b e  a b l e  t o  c o m p a r e 
these results with our analyses of the Tunisian, 
Lebanese and Moroccan populations. The role of 
BRCA2 in breast cancer in the Maghreb is also under 
study. 
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